Mainboard · BSE and NSEDraft filed

Claroid Pharmaceuticals Limited IPO: dates, price band, lot size, objects of the issue

Get updates on this IPO

Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.

Dates, allotment, listing and analyst views. Stop anytime.

By continuing you agree to the Terms and Privacy policy

Updated Sun 15 Nov 2026, 8:04 pm IST · Source: DRHP dated Tue 22 Sep 2026

Key facts

Price band
Not announced
Lot size
Not announced
Lot amount at the upper band
Not announced
Issue size at the upper band
1,26,00,000 shares (Amount not stated in the draft)
DRHP dated Tue 22 Sep 2026, page 79
Fresh issue
74,50,000 shares (Amount not stated in the draft)
DRHP dated Tue 22 Sep 2026, page 79
Offer for sale
51,50,000 shares (Amount not stated in the draft)
DRHP dated Tue 22 Sep 2026, page 79
Bid dates
Not announced
Listing date
Not announced
Risk factors
74
DRHP dated Tue 22 Sep 2026, page 78
Proposed exchanges
BSE and NSE

Timeline (IST)

  1. Draft filedWed 30 Sep 2026 confirmedDRHP dated Tue 22 Sep 2026
  2. OpensDates to be announced
  3. ClosesDates to be announced
  4. AllotmentDates to be announced
  5. Refund and unblockDates to be announced
  6. ListingDates to be announced

Objects of the issue

ObjectAmount
Funding of capital expenditure requirement for setting up of the Proposed Plant₹167.97 crore
General Corporate PurposesNot stated in the draft
TotalNot stated in the draft

The offer for sale goes to the selling shareholders, not the company. DRHP dated Tue 22 Sep 2026, page 125

Company and promoters

As described in the DRHP

We are a pharmaceutical formulations manufacturing company engaged in the development and manufacture of generic pharmaceutical products, comprising tablets and ointments and the encapsulation of pharmaceuticals formulations into hard gelatin capsules. Our business model is primarily focused on export of pharmaceutical products to semi-regulated international markets, particularly in Africa.

DRHP dated Tue 22 Sep 2026, page 255

Promoters

  • 5 individual promoters

DRHP dated Tue 22 Sep 2026, page 326

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group100%Not stated in the DRHP

DRHP dated Tue 22 Sep 2026, page 118

Financials (restated)

ItemFiscal 2026Fiscal 2025Fiscal 2024
Revenue from operations₹169.72 crore₹99.70 crore₹63.00 crore
Profit after tax₹22.70 crore₹7.22 crore₹4.12 crore
Net worth₹44.38 crore₹21.69 crore₹14.47 crore
Total borrowingsNot stated in the draftNot stated in the draftNot stated in the draft

DRHP dated Tue 22 Sep 2026, page 84

Who is selling in the offer for sale

Selling shareholderTypeShares offeredAmount at the upper band
Individual shareholderIndividual10,55,750Not announced
Individual shareholderIndividual4,73,800Not announced
Individual shareholderIndividual9,78,500Not announced
Individual shareholderIndividual9,61,332Not announced
Individual shareholderIndividual9,85,367Not announced
Individual shareholderIndividual5,06,416Not announced
Individual shareholderIndividual17,167Not announced
Individual shareholderIndividual17,167Not announced
Individual shareholderIndividual17,167Not announced
Individual shareholderIndividual17,166Not announced
Individual shareholderIndividual17,167Not announced
Individual shareholderIndividual17,167Not announced
Individual shareholderIndividual17,167Not announced
Individual shareholderIndividual17,166Not announced
Individual shareholderIndividual17,167Not announced
Individual shareholderIndividual17,167Not announced
Individual shareholderIndividual17,167Not announced
Total offer for saleNot stated in the draft

DRHP dated Tue 22 Sep 2026, page 79

Peer comparison (as in the DRHP)

Name of the CompanyConsolidated/ StandaloneRevenue from Operations (₹ in Lakhs)Face Value per equity share (₹)Market PriceEPS (Basic and Diluted) (₹)P/E ratioRoNW (%)NAV (per equity share) (₹)
Claroid Pharmaceuticals LimitedStandalone16,971.5310[●]5.41[●]51.16%10.57
Bafna Pharmaceuticals LtdStandalone15,061.7410329*4.6999.90*15.31%40.64
Syncom Formulations (India) LtdConsolidated48,917.15119.80*0.8121.90*20.21%4.41
Lincoln Pharmaceuticals LtdConsolidated67,102.9910606*43.8812.60*11.80%378.25

Reproduced from the DRHP dated Tue 22 Sep 2026, page 187; InsightPier adds no figures

Risk factors

74 total
  1. Most revenue comes from exports to Nigeria, so problems in Nigeria or in India-Nigeria trade could hurt the business (DRHP page 33)
  2. The top ten customers provide most product sales; losing any of them could hurt results (DRHP page 34)
  3. Tablets make up about half of product sales; trouble in this segment could hurt the business (DRHP page 35)
  4. Heavy reliance on exports exposes the company to international business risks (DRHP page 36)
  5. Failure to obtain or renew licences and approvals, or changes in regulation, could hurt operations (DRHP page 37)

All 74 risk factors, DRHP pages 32 to 78

Offer document

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts